Two new studies published on Wednesday of patients with breast and prostate cancers add to growing evidence that detecting bits of cancer DNA circulating in the blood can guide patient treatment.
Enthusiasm is building for "liquid biopsies," which offer a noninvasive alternative to standard tissue biopsies and are expected to be a multibillion-dollar market.
But a key question remains: Do they really work?
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.